Welcome to our dedicated page for Fusion Pharmaceuticals Common Shares news (Ticker: FUSN), a resource for investors and traders seeking the latest updates and insights on Fusion Pharmaceuticals Common Shares stock.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) is a clinical-stage oncology company based in Hamilton, Ontario, Canada, and Boston, focusing on the development of next-generation radioconjugates (RCs) for precision cancer treatments. The company specializes in targeted alpha therapy (TAT), leveraging their unique expertise in linking alpha particle-emitting isotopes to targeting molecules to create highly effective therapeutics.
Fusion’s lead program, FPI-2265, is designed specifically for metastatic castration-resistant prostate cancer (mCRPC). This innovative treatment targets the prostate-specific membrane antigen (PSMA) and is currently undergoing a Phase 2 clinical trial. FPI-2265 aims to improve patient outcomes by delivering a potent radioactive payload directly to cancer cells, minimizing damage to healthy tissues. The recent Phase 2 TATCIST trial results, presented at the AACR Annual Meeting 2024, demonstrated promising clinical activity and safety, with meaningful improvements in secondary endpoints for mCRPC patients.
Fusion’s pipeline includes several other promising candidates, such as FPI-1434, targeting the insulin growth factor 1 receptor (IGF1R), FPI-2059, targeting the neurotensin receptor 1 (NTSR1), and FPI-2068, a bispecific IgG-based RC targeting EGFR-cMET.
The recent acquisition of Fusion by AstraZeneca marks a significant milestone. AstraZeneca will acquire all of Fusion’s outstanding shares for $21.00 per share in cash, plus a non-transferable contingent value right of $3.00 per share, subject to achieving specific regulatory milestones. This acquisition, valued at approximately $2.4 billion, underscores Fusion's pivotal role in pioneering RCs and enhancing AstraZeneca's oncology portfolio.
Fusion operates a state-of-the-art Good Manufacturing Practice (GMP) compliant facility, ensuring the production of clinical doses for its expanding pipeline. The company has strategic actinium supply agreements with Niowave, Inc., and BWXT Medical to meet the growing demand for their therapies.
With a robust pipeline, strategic partnerships, and a strong balance sheet, Fusion is well-positioned to advance their mission of transforming cancer treatment through innovative alpha-emitting radioconjugates.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) recently acquired an IND for a Phase 2 clinical trial evaluating 225Ac-PSMA I&T, targeting metastatic castration-resistant prostate cancer (mCRPC). The company reported a net loss of $24.6 million for Q4 2022, and cash reserves totaled $186.6 million, projected to last into Q1 2025. Fusion is advancing multiple trials, including FPI-1434 with preliminary data expected in Q2 2023 and ongoing Phase 1 trials for FPI-1966 and FPI-2059. They announced a partnership with BWXT Medical for actinium-225 supply, critical for their targeted alpha therapies development.
Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), a clinical-stage oncology company, announced on March 8, 2023, that its compensation committee granted stock option awards for 21,000 shares of common stock to a new employee. This grant is in compliance with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize the employee's engagement. The options come with an exercise price of $4.63 per share, matching the closing price on March 6, 2023. Each option has a ten-year term and vests over four years. Fusion's portfolio includes several promising drugs currently in various phases of clinical trials, targeting multiple cancer-related pathways.
Fusion Pharmaceuticals (NASDAQ: FUSN), a clinical-stage oncology company, announced its participation in a panel titled "Novel Oncology Targets" at the 43rd Annual Cowen Healthcare Conference, scheduled for March 7, 2023, at 9:10 a.m. ET. CEO John Valliant, Ph.D. will represent the company during this event. A live webcast will be available on the company's website, with an archived replay accessible for 30 days post-presentation. Fusion focuses on next-generation radiopharmaceuticals, including its clinical pipeline with products targeting prostate cancer and other malignancies. The company also collaborates with AstraZeneca and Merck for novel therapies.
Fusion Pharmaceuticals has announced the acquisition of a Phase 2 clinical trial program from RadioMedix, focusing on a targeted alpha therapy for metastatic castration-resistant prostate cancer, known as FPI-2265. The transaction includes a $60.0 million private placement financing, expected to close by February 16, 2023. This addition enhances Fusion's pipeline of innovative therapies, as the TATCIST trial aims to treat patients with a significant unmet need. Fusion anticipates having approximately $248.0 million in cash post-financing, supporting its operations into the first quarter of 2025.
Fusion Pharmaceuticals, a clinical-stage oncology firm, announced its participation in a fireside chat at the SVB Securities Virtual Global Biopharma Conference scheduled for February 15, 2023, at 12:00 p.m. ET. Key executives, including CEO John Valliant and CSO Christopher Leamon, will present. A live webcast will be available on the company's website, with a replay accessible for 90 days post-event. Fusion specializes in next-generation radiopharmaceuticals, with ongoing clinical trials for therapies targeting IGF-1R, FGFR3, and NTSR1. Collaborations with AstraZeneca and Merck enhance its pipeline of targeted alpha therapies.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announced the grant of stock option awards totaling 161,000 shares to two new employees, as part of an inducement under Nasdaq Listing Rule 5635(c)(4). The options, with an exercise price of $3.35 per share, mirror the closing price on February 6, 2023. Each option has a ten-year term and vests over four years, with 25% vesting after one year and the rest in equal installments over the following three years. Fusion is engaged in developing innovative radiopharmaceuticals, with ongoing Phase 1 clinical trials for several programs, including FPI-1434 and collaborations with AstraZeneca and Merck.
Fusion Pharmaceuticals (Nasdaq: FUSN) reported advancements in its pipeline of targeted alpha therapies (TATs) as of January 6, 2023. The company plans to submit an investigational new drug application for FPI-2068 in Q1 2023 and expects Phase 1 data for FPI-1434 in Q2 2023. Patient enrollment is ongoing for FPI-1966, with clinical data anticipated in 2024. A new partnership with BWXT Medical enhances actinium supply, supporting the pipeline's growth. CEO John Valliant highlighted Fusion's commitment to developing precision oncology therapies, positioning the company for a promising year.
Fusion Pharmaceuticals Inc. and BWXT Medical have announced a preferred partner agreement for the supply of actinium-225, vital for targeted alpha therapies. This agreement ensures Fusion's access to high-purity actinium needed for its expanding clinical pipeline, which includes three proprietary programs in trials. BWXT Medical, a leader in medical isotopes, will provide actinium at volume-based pricing, enhancing Fusion's supply chain and supporting future growth. The collaboration aims to meet the growing demand for effective cancer treatments utilizing alpha-emitting isotopes.
Fusion Pharmaceuticals and BWXT Medical have established a preferred partner agreement for the supply of actinium-225, enhancing Fusion's existing isotope supply for its clinical-stage radiopharmaceuticals. This strategic partnership is poised to support growing demand for targeted alpha therapies (TATs) while ensuring volume-based pricing. The collaboration emphasizes BWXT's commitment to meeting the global actinium supply needs, bolstering Fusion's clinical programs and future business opportunities.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announced the grant of stock options for 13,200 shares to a new employee, complying with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $2.36 per share, matching the company's closing stock price on December 5, 2022. Each option has a ten-year term, with 25% vesting after one year and the remainder vesting monthly over three years. Fusion develops next-gen radiopharmaceuticals, with ongoing clinical trials for its products targeting specific receptors. Collaborations with AstraZeneca and Merck further enhance its research.
FAQ
What is the current stock price of Fusion Pharmaceuticals Common Shares (FUSN)?
What is the market cap of Fusion Pharmaceuticals Common Shares (FUSN)?
What does Fusion Pharmaceuticals Inc. specialize in?
What is Fusion's lead program?
What recent achievement has Fusion Pharmaceuticals accomplished?
What is the significance of the acquisition by AstraZeneca?
Which other products are in Fusion Pharmaceuticals' pipeline?
What was revealed in the Phase 2 TATCIST trial of FPI-2265?
Where is Fusion Pharmaceuticals headquartered?
What type of facility does Fusion operate for manufacturing?
Who are Fusion's strategic supply partners?
What financial terms were involved in AstraZeneca's acquisition of Fusion?
